Spinal Concepts joins with Selective to develop new product in bone growth gene race
This article was originally published in Clinica
Private US companies Spinal Concepts and Selective Genetics are to link up in a joint development programme that will combine Selective's gene activated matrices (GAM) with Spinal's InFix and other interbody fusion devices.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.